|Bid||3.4100 x 1000|
|Ask||3.7900 x 2900|
|Day's Range||3.3000 - 3.4600|
|52 Week Range||3.2000 - 12.8900|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2019 - Mar 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.75|
WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc.
By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT We are raising our target valuation for EyeGate Pharmaceuticals (NASDAQ:EYEG) from $12.00 to $15.00 based on solid progress in its existing pipeline and the introduction of a new candidate for treating bacterial conjunctivitis. Since early 2019, the Company focused all its efforts on its OBG (Ocular Bandage Gel) platform
Stephen From has been the CEO of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) since 2005, and this article will examine...